Ischemic heart disease affects millions of people around the world. Current treatment options, including coronary artery bypass grafting, do not result in full functional recovery, highlighting the need for novel adjunctive therapeutic approaches. Hibernation describes the myocardial response to prolonged ischemia and involves a set of complex cytoprotective metabolic and functional adaptations. PGC1-alpha, a key regulator of mitochondrial energy metabolism and inhibitor of oxidant-stress-inflammatory signaling, is known to be downregulated in hibernating myocardium. PGC1-alpha is a critical component of cellular stress responses and links cellular metabolism with inflammation in the ischemic heart. While beneficial in the acute setting, a chronic state of hibernation can be associated with self-perpetuating oxidant stress-inflammatory signaling which leads to tissue injury. It is likely that incomplete functional recovery following revascularization of chronically ischemic myocardium is due to persistence of metabolic changes as well as prooxidant and proinflammatory signaling. Enhancement of PGC1-alpha signaling has been proposed as a possible way to improve functional recovery in patients with ischemic heart disease. Adjunctive mesenchymal stem cell therapy has been shown to induce PGC1-alpha signaling in hibernating myocardium and could help improve clinical outcomes for patients undergoing bypass surgery.
Diastolic dysfunction persists despite coronary artery bypass graft surgery (CABG) in patients with hibernating myocardium (HIB). We studied whether the adjunctive use of a mesenchymal stem cells (MSCs) patch during CABG improves diastolic function by reducing inflammation and fibrosis. HIB was induced in juvenile swine by placing a constrictor on the left anterior descending (LAD) artery, causing myocardial ischemia without infarction. At 12 weeks, CABG was performed using the left-internal-mammary-artery (LIMA)-to-LAD graft with or without placement of an epicardial vicryl patch embedded with MSCs, followed by four weeks of recovery. The animals underwent cardiac magnetic resonance imaging (MRI) prior to sacrifice, and tissue from septal and LAD regions were collected to assess for fibrosis and analyze mitochondrial and nuclear isolates. During low-dose dobutamine infusion, diastolic function was significantly reduced in HIB compared to the control, with significant improvement after CABG + MSC treatment. In HIB, we observed increased inflammation and fibrosis without transmural scarring, along with decreased peroxisome proliferator-activated receptor-gamma coactivator (PGC1α), which could be a possible mechanism underlying diastolic dysfunction. Improvement in PGC1α and diastolic function was noted with revascularization and MSCs, along with decreased inflammatory signaling and fibrosis. These findings suggest that adjuvant cell-based therapy during CABG may recover diastolic function by reducing oxidant stress–inflammatory signaling and myofibroblast presence in the myocardial tissue.
Background: Human Epididymis Protein 4 (HE4), a biomarker in ovarian cancer, is increased in pulmonary fibrosis. Hypoxia, a typical feature of interstitial lung disease (ILD), induces HE4. The anti-diabetic drug dapagliflozin might counteract the effects of HE4. Aims: Assess fibrogenic and inflammatory effects of HE4 from hypoxia-stimulated epithelial cells on pulmonary fibroblasts and determine the potential role of dapagliflozin in inhibiting HE4 action. Methods: Bronchial epithelial cells (16HBE14o-, HBE) were exposed to hypoxia (6h 1%O2) in the presence/absence of HE4 siRNA (siHE4) or dapagliflozin (0-10µM) and the conditioned medium (CM) collected. Pulmonary fibroblasts (CCD11-Lu) were exposed to recombinant huHE4 (rHE4) or CM (10%). HE4, IL-8/6 and collagen were assessed by ELISA and Sirius Red staining, respectively. Results: A systematic review with meta-analysis of 22 studies (n = 2049) showed significantly increased HE4 gene expression in ILDs compared to non-fibrotic lung diseases (SMD 0.79 (0.57,1.00), p<0.00001). rHE4 and hypoxia CM induced collagen deposition and cytokine secretion from fibroblasts. HBE siHE4-CM did not show differences in IL8/6, but increased collagen deposition from CM-exposed fibroblasts. Dapagliflozin dose-dependently reduced hypoxia-induced HE4 and IL-8 release from HBE and the collagen deposition and IL-8 release from fibroblasts. Conclusions: HE4 is upregulated in ILDs and has an important role in regulating fibrosis and inflammation. Compared to siRNA, reducing HE4 by dapagliflozin has additional anti-inflammatory effects that may contribute to its antifibrotic effect in our model of lung fibrosis. Future studies need to determine the suitability of HE4 as a therapeutic target.